Topic Review
Innovative Strategies in Microvascular Head and Neck Reconstruction
The field of reconstructive microsurgery has witnessed considerable advancements over the years, driven by improvements in technology, imaging, surgical instruments, increased understanding of perforator anatomy, and experience with microsurgery. However, within the subset of microvascular head and neck reconstruction, novel strategies are needed to improve and optimize both patient aesthetics and post-operative function. Given the disfiguring defects that are encountered following trauma or oncologic resections, the reconstructive microsurgeon must always aim to innovate new approaches, reject historic premises, and challenge established paradigms to further achieve improvement in both aesthetic and functional outcomes. 
  • 214
  • 24 Aug 2023
Topic Review
Paediatric Formulation Development and Overcoming Taste-Masking Challenges
Despite regulatory incentives in the United States and Europe to promote paediatric formulation development, progress is hampered by challenges including the need to address dose flexibility, swallowability, palatability, and the diverse physiological developmental stages encountered in the paediatric population. Peroral minitablets, microparticles, granules, liquid formulations, and scored chewable tablets have been proposed to address dose flexibility and provide ease of swallowability. However, given that one in four active pharmaceutical ingredients (APIs) have an intensely bitter taste and these formulations often result in drug interactions with taste receptors, palatability remains a significant challenge as young children are highly sensitive to bitter taste. This issue is especially prevalent for drugs required to be administered at high doses and frequent intervals, for example, anti-infectives, where the problem is further compounded by the high number (40%) of anti-infective APIs having an objectionable taste.
  • 318
  • 24 Aug 2023
Topic Review
Expression and Subcellular Localization of PCAT6
Prostate cancer-associated transcript 6 (PCAT6), as a newly discovered carcinogenic long non-coding RNA (lncRNA), is abnormally expressed in multiple diseases. PCAT6 is also named KDM5B-AS1, KDM5BAS1, PCAN-R1, ncRNA-a2, or onco-lncRNA-96. It was first described as ncRNA-a2 in 2010. The gene of PCAT6 is located on chromosome 1q32.1 and contains two exons. It consists of 968 bp and has two transcript variants: transcript variant 1 (NR_046325.1) and transcript variant 2 (NR_046326.1).
  • 398
  • 24 Aug 2023
Topic Review
Stabilization of Essential Oil
Essential oils (EOs) have stability problems, including volatility, oxidation, photosensitivity, heat sensitivity, humidity sensitivity, pH sensitivity, and ion sensitivity. A drug delivery system is an effective way to stabilize EOs, especially due to the protective effect of polymeric drug carriers. Polysaccharides are frequently employed as drug carrier materials because they are highly safe, come in a variety of forms, and have plentiful sources.
  • 436
  • 24 Aug 2023
Topic Review
Structure and Function of UHRF1
Cancer is one of the leading causes of death worldwide, and its incidence and mortality are increasing each year. Improved therapeutic strategies against cancer have progressed, but remain insufficient to invert this trend. Along with several other risk factors, abnormal genetic and epigenetic regulations play a critical role in the initiation of cellular transformation, as well as tumorigenesis. The epigenetic regulator UHRF1 (ubiquitin-like, containing PHD and RING finger domains 1) is a multidomain protein with oncogenic abilities overexpressed in most cancers. Through the coordination of its multiple domains and other epigenetic key players, UHRF1 regulates DNA methylation and histone modifications. This well-coordinated dialogue leads to the silencing of tumor-suppressor genes (TSGs) and facilitates tumor cells’ resistance toward anticancer drugs, ultimately promoting apoptosis escape and uncontrolled proliferation. Several studies have shown that the downregulation of UHRF1 with natural compounds in tumor cells induces the reactivation of various TSGs, inhibits cell growth, and promotes apoptosis.
  • 403
  • 24 Aug 2023
Topic Review
Vertigo Associated with Otosclerosis and Stapes Surgery
Otosclerosis is a pathological condition affecting the temporal bone, and is characterized by remodelling of the labyrinthine bone tissue through a dynamic process of osteolysis and osteogenesis. This condition progressively leads to hearing loss, tinnitus, and vertigo.
  • 369
  • 24 Aug 2023
Topic Review
From Circulating Tumor Cells to Mirna
Medullary thyroid carcinoma (MTC) is a malignant tumor that arises from parafollicular C cells, which are responsible for producing calcitonin. The majority (75%) of MTC cases are sporadic forms, while the remaining (25%) have a hereditary component. In these hereditary cases, MTC can occur in conjunction with other endocrine disorders (i.e., pheochromocytoma) or as an isolated condition known as familial medullary thyroid carcinoma. The primary genetic mutation associated with the development of MTC, regardless of its hereditary or sporadic nature, is a point mutation in the RET gene. Evaluation of serum calcitonin levels represents the most reliable and sensitive marker for both the initial diagnosis and the postsurgical monitoring of MTC. Unfortunately, most patients do not achieve normalization of postsurgical serum calcitonin (CT) levels after surgery. Therefore, there is a need to find new biomarkers to be used with serum CT in order to increase test sensitivity and specificity.
  • 132
  • 24 Aug 2023
Topic Review
Salivary Amino Acid Levels in Cancer
Amino acids, as a raw material for protein synthesis and a product of protein metabolism, enter the body or are synthesized endogenously. They play mainly physiological roles as major metabolites and regulators of metabolism among the most important compounds.
  • 285
  • 24 Aug 2023
Topic Review
Updates in Culture-Negative Endocarditis
Blood culture-negative infective endocarditis (BCNE) is a challenging condition associated with significant morbidity and mortality.
  • 212
  • 24 Aug 2023
Topic Review
Novel Cellular and Immunotherapy
Targeted cellular and immunotherapies have welcomed a new chapter in multi-modal cancer therapy. These agents harness our innate immune system and destroy malignant cells in a precise way as compared with “legacy” chemotherapeutic agents that largely rely on abolishing cell division. New therapies can augment the T-cell recognition of tumor antigens and effectively prevent tumor cells from their historically successful ability to evade immune recognition. These novel agents cause acute and chronic toxicities to a variety of organ systems (enteritis, pneumonitis, hypophysitis, and hepatitis), and this may masquerade as other chronic illnesses or paraneoplastic effects. As the perioperative footprint of cancer patients increases, it is essential that perioperative providers—anesthesiologists, surgeons, nurse anesthetists, and inpatient hospital medicine providers—be up to date on the physiologic mechanisms that underlie these new therapies as well as their acute and subacute toxicity profiles. Immunotherapy toxicity can significantly impact perioperative morbidity as well as influence perioperative management, such as prophylaxis for adrenal insufficiency, preoperative pulmonary assessment, and screening for thyroid dysfunction, among others.
  • 210
  • 24 Aug 2023
  • Page
  • of
  • 1349
Video Production Service